HHS Should Encourage Prospective Outcome Studies of Pharmacogenetic Drug Dosing, SACGHS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
One example of the value of genotyping is Genentech's Herceptin, committee members agreed.
You may also be interested in...
FDA Signs Cooperative Agreement To Develop Standards For Warfarin-Dosing Biomarkers
The Critical Path Institute, in conjunction with the University of Utah, will be awarded $750,000 in funding by FDA to be used, in part, to validate and standardize genetic testing for biomarkers related to warfarin efficacy and metabolism.
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.